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A B S T R A C T
The objective of this study was to determine and compare the humoral and cellular immune responses of calves
exposed to a single dose of Bovela® bovine viral diarrhea virus (BVDV) live double deleted vaccine or a ﬁeld
strain virus (FSV) of BVDV type 2 (strain 890). Thirty seronegative, colostrum-deprived 5 month-old Holstein
steer calves that tested negative for persistent BVDV by ear notch immunohistochemistry and seronegative to
BVDV types 1 and 2 were used. Calves were screened by multi-parameter ﬂow cytometry (MP-FCM) 1 week
before vaccination to ensure that they were negative for T cell responses to the BVDV types 1 and 2 viruses in the
Bovela® vaccine. Calves were assigned to 3 treatment groups: control (PBS), FSV inoculated, and Bovela®
vaccinated. The humoral response was tested by standard serum virus neutralization (SVN) test to BVDV types 1
(Singer strain) and 2 (strain 125). The response by CD4, CD8, and gamma delta (γδ TCR) T cells was evaluated by
MP-FCM using individual BVDV types 1 and 2 from Bovela® vaccine as recall antigens at 5, 6, and 7 weeks after
vaccination. Activation markers used were upregulation of surface CD25 (IL-2R), intracellular interferon gamma
(IFNγ) and intracellular interleukin 4 (IL-4). Each T cell subset was evaluated for increased expression of each
activation marker compared to non-antigen stimulated cells of the same animal. All Bovela® vaccinated and FSV
inoculated calves produced SVN antibodies to both BVDV types 1 and 2 while control animals remained
seronegative throughout the study. The mean (weeks 5, 6, and 7) T cell recall responses to Bovela® BVDV type 1
and type 2 recall antigens were numerically higher in all three T cell subsets (CD4, CD8, and γδ TCR) for all three
activation markers (CD25, IFNγ, and IL-4) when compared to either the control animals or to the FSV inoculated
animals. These diﬀerences were often, but not always, statistically signiﬁcant (P < 0.05)
1. Introduction
Bovine viral diarrhea virus (BVDV) causes a variety of clinical
syndromes in cattle including respiratory disease, reproductive dysfunc-
tion, immunosuppression, persistent infection and mucosal disease
resulting in signiﬁcant economic losses (reviewed in Lanyon et al.,
2014). A large number of vaccines for BVDV are available in the U.S.
These vaccines are either conventional inactivated and adjuvanted
vaccines or modiﬁed live virus (MLV) vaccines with reduced virulence
(Ridpath, 2013; Griebel, 2015). Vaccination of cows to protect the fetus
from infection is essential to prevent abortion, fetal malformations, and
the birth of persistently infected (PI) calves (Griebel, 2015). PI animals
are the major source of transmission of BVDV within and between herds
(Moennig and Becher, 2015). Killed vaccines are viewed as being safer
than MLV vaccines but are not as eﬀective at inducing aspects of T cell-
mediated immunity and providing protection from a diversity of BVDV
strains (Platt et al., 2008; Ridpath, 2013; Griebel, 2015; Downey-
Slinker et al., 2016). MLV vaccines have been shown to induce a more
complete T cell-mediated immune response (Platt et al., 2006) and to be
more capable of protecting pregnant animals and their fetuses from
infection (Newcomer et al., 2015; Griebel, 2015). They can also be
eﬀective in inducing protection from challenge and memory CD4, CD8
and γδ TCR T cell responses, but not antibody, in young calves in the
presence of maternal antibody (Platt et al., 2009) However, most MLV
BVD vaccines are not safe for use in pregnant animals that are not
already immune and should not be used in calves nursing pregnant
animals that are not immune. Some MLV vaccines in the US are
approved for use in pregnant animals that have previously been
vaccinated. However, since vaccines are not capable of protecting
100% of vaccinated animals, there is some concern associated with
using MLV vaccines in pregnant animals, even if they have previously
been vaccinated.
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A new BVDV vaccine has been developed based on genetic
modiﬁcation of the vaccine virus to inactivate the Erns and Npro genes
of both the BVDV types 1 and 2 strains of virus in the vaccine (Meyer
et al., 2007). These viruses have been tested for safety in seronegative
pregnant heifers and cows and shown to be incapable of crossing the
placenta (Meyer et al., 2007). The objective of the research reported
here was to determine if this genetically modiﬁed BVDV MLV vaccine is
capable of inducing SVN antibodies and CD4, CD8 and γδ TCR T cell
responses as other MLV BVDV vaccines have been shown to do.
2. Materials and methods
2.1. Animals and experimental design
Thirty 5 month-old colostrum-deprived Holstein steer calves that
tested negative for persistent BVDV by immunohistochemistry on ear
notches and seronegative (SVN titers< 2) to BVDV types 1 (Singer
strain) and 2 (strain 125) viruses were used. The calves were housed in
open front sheds near Ames, IA, USA in March through May 2016. They
were allowed a 2-week acclimation period prior to the experiment. The
timeline, treatment and tests performed are outlined in Table 1. Calves
were assigned a number using the Excel random number generator,
then sorted by ascending random number to assign 10 animals each to
the three treatment groups: PBS control group; ﬁeld strain BVDV type 2
strain 890 (FSV) inoculated group and Bovela® vaccinated group. All
treatments were administered intramuscularly. Each treatment group
was housed separately in a single pen with no contact with other
treatment groups. Calves were provided water, ad libitum from the
facility site well and ad libitum access to grass hay. Calves were fed a
commercial complete pelleted ration (Purina Calf Growena
®
) at a rate of
approximately 5 lbs. per head per day. Calves were observed daily from
week −2 through week 7 by a trained animal observer who was
blinded to treatment groups. Parameters observed and recorded
included: attitude, appetite, nasal discharge, ocular discharge, respira-
tory character, cough and fecal consistency. All animal related proce-
dures were approved by the Veterinary Resources, Inc. Animal Care and
Use Committee (Table 2).
2.2. Vaccine and viruses
The vaccine used was Bovela® live double deleted BVDV vaccine
(serial # 241-013) containing both BVDV types 1 and 2 strains at a
minimum titer of 103 TCID50 of each strain per 2 mL dose. The Bovela®
vaccine is not currently licensed by the USDA Center for Veterinary
Biologics and is not currently available for use in the United States. The
2 BVDV strains in the Bovela® vaccine were non-cytopathic double
deletion mutants. The parent strain for the BVDV type 1 fraction was
KE-9 originally isolated in Germany and for the BVDV type 2 fraction
was NY-93 originally isolated in the U.S. Both strains had identical
genetic modiﬁcation by deletion of the coding region of amino acid 349
located in the coding sequence for Erns, and deletion of the coding
region for the whole Npro protein, except the N-terminal four codons.
Both the Erns and Npro proteins were known to be important virulence
factors due to their inhibition of interferon production by the infected
cell.
The ﬁeld strain virus used for intramuscular inoculation of the FSV
group was BVDV type 2 strain 890 (provided by Dr. Julia Ridpath at the
USDA National Animal Disease Center in Ames, IA) at 2 × 107 TCID50/
animal.
The viruses used as recall antigens to stimulate PBMCs in the MP-
FCM assay were BVDV type 1 Bovela® vaccine strain 241-033115-1 and
BVDV type 2 Bovela® vaccine strain 241-033115-2, both used at 105.5
TCID50/mL.
In addition, EDTA blood samples were collected on days −3, −2,
−1, 4, 6, 8, 11, 13, and 15 for total and diﬀerential white blood cell
counts (conducted by the Clinical Pathology Laboratory, College of
Veterinary Medicine, Iowa State University).
2.3. Serum virus neutralization antibody assays
Serum samples for the SVN tests were separated on collection day
and frozen at −20 °C until tested. Speciﬁc SVN antibody to cytopathic
BVDV type 1 (Singer strain) and type 2 (strain 125) were assayed by the
Veterinary Diagnostic Laboratory, College of Veterinary Medicine, Iowa
State University.
2.4. Multi-parameter ﬂow cytometry (MP-FCM)
Whole blood samples (10 mL) were collected in 2 mL of 2 x acid
citrate dextrose (0.15 M sodium citrate, 0.076 M citric acid monohy-
drate, and 0.287 M dextrose). Buﬀy coats were collected and peripheral
blood mononuclear cells (PBMC) were isolated as previously described
(Platt et al., 2006). The MP-FCM assay was performed as previously
described (Platt et al., 2009). Brieﬂy, buﬀy coats were collected by
centrifugation at 1,000xg for 20 min. PBMC were isolated by lysing the
contaminating RBC with 2 vols of buﬀered water (deionized water with
0.15 M Na2HPO4 and 0.15 M KH2PO4) for 1 min followed by 1 vol of
3xPBS and centrifuged at 400xg for 10 min. then resuspended in RPMI
++ (RPMI with 15% FBS and 1.5% penicillin/streptomycin solution)
to 5 × 106 cells/mL. Two hundred μL of each PBMC suspension
containing 106 cells, were added to each of 7 wells of a 96-well ﬂat-
bottomed tissue culture microtiter plate. Two wells each received 50 μL
RPMI ++ as a non-antigen stimulated control. Two wells each
received 50 μL of Bovela® BVDV type 1, and Bovela® BVDV type 2.
Another well received 50 μL concanavalin A (Con A) at 5 μg/well as the
mitogen control. The plates were incubated in a 5% CO2 humidiﬁed
incubator at 37 °C for 4 days. After 4 days incubation, PBMC were
mixed with 50 μL protein transport inhibitor Brefeldin A at the
concentration recommended by the manufacturer and transferred to
Table 1
Timeline, Treatment, and Tests. MP-FCM=Multi-Parameter Flow Cytometry.
SVN = Serum Virus Neutralization.
Week Treatment (all groups) Test
−2 to 0 Acclimation period
−1 Collect serum and whole blood MP-FCM
0 Administer treatments:
−2 to 7 Daily animal observations
5 Collect serum and whole blood MP-FCM& SVN tests
6 Collect serum and whole blood MP-FCM& SVN tests
7 Collect serum and whole blood MP-FCM& SVN tests
Table 2
Summary of antibodies and reagents used in this study: each dilution used in this study
was derived from titration of their optimal performance in the MP-FCM protocol for the
particular lot of each reagent.
Primary antibody Isotype Dil 1: Secondary
reagent
Dye Dil 1:
Surface staining
Mouse x bovine
CD4
IgG2a 500 Goat x Mouse
IgG2a
PE-TR 200
Mouse x bovine
CD8
IgM 500 Rat x Mouse IgM PerCP-
Cy5.5
100
Mouse x bovine γδ
TCR
IgG2b 500 Goat x Mouse
IgG2b
AF647 1000
Mouse x bovine
CD25
IgG3 500 Goat x Mouse
IgG3
PE 500
Intracellular staining
Mouse x bovine
IFNγ-biotin
IgG1 50 Streptavidin PE-Cy7 100
Rabbit x bovine IL-
4
Rabbit Pab 25 Goat x Rabbit IgG AF700 100
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96-well round-bottomed tissue culture microtiter plates. The plates
were incubated in the same condition for an additional 4 h. PBMC were
washed once with 150 μL PBS ++ (PBS with 0.5% bovine serum
albumin, and 0.1% sodium azide). All microplate wash cycles were
performed at 300 × g for 1 min. The list of antibodies and reagents
used in this study are summarized in Table 1. Primary monoclonal
antibody mix (50 μL) was added to all wells. The monoclonal primary
antibody mix consisted of mouse anti-bovine CD4 isotype IgG2a (clone
IL11A), mouse anti-bovine CD8 isotype IgM (clone BAQ111A), mouse
anti-bovine γδ TCR isotype IgG2b (clone GB21A), and mouse anti-
bovine CD25 isotype IgG3 (clone LCTB2A). All primary monoclonal
antibodies were purchased from Washington State University (WSU)
Fig. 1. Means (± SEM) total blood cell counts by type. Blood samples were collected on days −3, −2, −1, 4, 6, 8, 11, 13, and 15 of the experiment. Each cell type was counted and
averaged by day. Statistically signiﬁcant diﬀerences (P < 0.05) were analyzed between treatment groups. A indicates the diﬀerences between Bovela® and FSV groups compared to PBS
group. B indicates the diﬀerences between Bovela® group compared to FSV group.
Fig. 2. Means (± SEM) Log2 SVN titers to cytopathic BVDV type 1 (Singer strain) and BVDV type 2 (strain 125) from samples collected on weeks −1, 5, 6, and 7 of the experiment.
Values within the same week, not connected by the same letter are signiﬁcantly diﬀerent (P < 0.05).
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Monoclonal Antibody Center (Pullman, WA). All antibodies were
diluted to their previously titrated optimum dilutions. The plates were
incubated at room temperature (RT, approximately 25 °C) for 15 min.
After two wash cycles, the secondary antibody conjugate mix (50 μL)
was added to all wells. The secondary antibody conjugate mix consisted
of goat anti-mouse IgG2a-Phycoerythrin-Texas Red (PE-TR) (cat
#1080-10, Southern Biotech., Birmingham, AL), rat anti-mouse IgM-
perCP-Cy5.5 (cat # 550881, BD Biosciences, San Jose, CA), goat anti-
mouse IgG2b-Alexa Fluor 647 (AF647) (cat # A-21242, Thermo Fisher
Scientiﬁc, Waltham, MA) and goat anti-mouse IgG3-R-Phycoerythrin
(R-PE) (cat # 1100-09, Southern Biotech., Birmingham, AL). The plates
were incubated at RT for 15 min. After three wash cycles, 100 μL of cell
ﬁxing and permeabilizing solution (BD cytoﬁx-cytoperm, BD Bios-
ciences Pharmingen, San Diego, CA) was added to all wells and the
plates were incubated at RT for 30 min. The plates were washed once
with BD wash solution (BD Biosciences, San Diego, CA). The anti-
cytokine antibody mix (50 μL) was added to all wells. The primary
antibody mix for intracellular staining consisted of mouse anti-bovine
IFNγ-biotin (cat # MCA1783B, Bio-Rad, Raleigh, NC) and rabbit anti-
bovine IL-4 (cat # PBOIL41, Thermo Fisher Scientiﬁc, Waltham, MA).
The plates were incubated at RT for 15 min. After two wash cycles with
BD wash solution, the secondary reagents mix (50 μL) was added to all
wells. The secondary reagent consisted of streptavidin-PE-Cy 7 (cat #
SA1012, Thermo Fisher Scientiﬁc, Waltham, MA) and goat anti-rabbit
IgG-Alexa Fleur 700 (AF700) (cat # A-21038, Thermo Fisher Scientiﬁc,
Waltham, MA). The plates were incubated at RT for 15 min. Three more
wash cycles with BD wash solution were performed and 1% ultra-pure
formalin in PBS (125 μL) was added to all wells. Stained PBMCs were
transferred to ﬂow tubes and kept in the dark at 4 °C until ﬂow
cytometric analysis was performed.
Flow cytometric analysis was performed by personnel of the Cell
and Hybridoma Facilities at Iowa State University using a Canto
cytometer (BD Biosciences, San Diego, CA). FlowJo cell analysis soft-
ware (Ashland, OR) was used to analyze ﬂow cytometry data. The live
cells were gated and 3 major bovine T cell subsets, CD4, CD8, and γδ
TCR were identiﬁed. The percentages of each T cell subset expressing
CD25 (%CD25+) and their geometric mean ﬂuorescent intensities
(MFI) were collected. The CD25 EI (expression index) of each T cell
subset was calculated by dividing the averaged product (%CD25+ x
MFI) from 2 wells of antigen-stimulated cells by the averaged product
from 2 wells of non-antigen stimulated cells of the same subset of the
same animal. The IFNγ EI and IL-4 EI were calculated the same way as
CD25 EI.
2.5. Statistical analysis
The responses were analyzed using repeated measures analysis of
variance (ANOVA). Group, day and their interaction were used as ﬁxed
eﬀects, whereas calf was the subject of repeated measures. The
antibody data were log-transformed before analyses. Comparison
among groups were performed using F-test followed by post-hoc
Tukey’s t-tests for pairwise comparisons. A probability of p < 0.05
Fig. 3. Sample plots showing gating strategy to identify T cell subsets. The same gates from media control samples were placed on the same plots of the same samples stimulated by BVDV
antigens. Minor gate adjustments were applied as necessary to best ﬁt the population of each plot. The single cells were gated from FSC-H/FSC-A plots of the total cell counts. The live
cells were gated from single cell populations on SSC-H/FSC-A plots. Live cells were plotted on CD4/γδ TCR ﬂuorescent dyes to identify CD4 and γδ TCR populations. Populations of CD4-/
γδ TCR- cells were plotted on histograms and CD8 cells were identiﬁed.
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was considered statistically signiﬁcant for all tests.
3. Results
3.1. Clinical observations
Animals remained healthy throughout the study. The only abnormal
clinical signs observed were mild, transient ocular discharge. The
Bovela® group had two incidences of one day each and the FSV group
had ﬁve incidences of one day each of mild transient ocular discharge in
a total of 10 animals observed daily for 7 weeks after vaccination or
FSV inoculation.
3.2. Total and diﬀerential white blood cell counts
The means (± SEM) of total and diﬀerential white blood cell counts
are found in Fig. 1. The FSV group had signiﬁcantly (P < 0.05)
decreased total WBC counts compared to the PBS group and the Bovela®
group on most days when samples were evaluated from days 4–15 after
inoculation. The Bovela® group had signiﬁcantly (P < 0.05) lower
WBC counts than the PBS group on days 6 and 8 after inoculation. Both
the FSV and Bovela® groups had signiﬁcantly lower neutrophil counts
than the PBS group on some occasions between days 4 and 11 after
inoculation. The FSV inoculated cattle had signiﬁcantly (P < 0.05)
lower lymphocyte counts than the PBS and the Bovela® group from days
4 through 13 after inoculation. The lymphocyte counts for the
Bovela®group were very similar to the PBS group and were signiﬁcantly
higher than the FSV group for days 3 through 15. The means (± SEM)
of platelet counts are shown in Fig. 4. The FSV group had signiﬁcantly
lower platelet counts than the Bovela® group on days −1 through −3,
apparently due to random chance. After virus inoculation, the platelet
counts for the FSV group decreased and were signiﬁcantly lower than
the values for the PBS group on days 4 through 8. The platelet counts
for the Bovela® group also decreased on days 4 through 8 after
inoculation, but they were never signiﬁcantly lower than the values
for the PBS group. By day 11, the platelet counts for the FSV and
Bovela® groups increased and were numerically higher than the values
for the PBS group. At the end of the experiment, the platelet counts for
the FSV group (day 15) and Bovela® group (days 13 and 15) were
signiﬁcantly higher than the values for the PBS group.
3.3. Serum virus neutralization titers
The SVN titers to BVDV types 1 and 2 are shown in Fig. 2. The PBS
group remained seronegative throughout the observation period. The
FSV and Bovela® groups had similar SVN antibody titers against BVDV
type 1. However, the FSV group had titers to BVDV type 2 that were
several fold higher (P < 0.05) than the Bovela® group.
3.4. T cell responses to BVDV recall antigens as measured by multi-
parameter ﬂow cytometry
Sample plots showing gating strategies to identify T cell subsets and
to detect up-regulation of the 3 activation markers are shown in Figs. 3
and 4 respectively.
The MP-FCM results following PBMC stimulation with the 2
individual strains of Bovela® BVDV are found in Figs. 5 through 7.
For all T cell subsets combined, the Bovela® group had signiﬁcantly
higher EI values for all three T cell activation markers when BVDV type
1 and type 2 were each used as recall antigens. There were no instances
where the FSV group had higher EI values than the PBS group for all T
cell subsets combined.
The mean CD25 EI data is shown in Fig. 5. There were no signiﬁcant
diﬀerences in T cell subset responses between treatment groups when
Fig. 4. Sample histograms showing gating strategy to detect the up-regulation of 3 activation markers. The same gates from media control samples were placed on the same histogram
plots of the same samples stimulated by BVDV antigens. The percentages of positive cells and their mean ﬂuorescent intensities were used to calculate the corresponding expression
indices.
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evaluated before the experiment. The CD25 EI was always signiﬁcantly
(P < 0.05) higher for the Bovela® group than the PBS group for each T
cell subset evaluated. The Bovela® group results were also signiﬁcantly
(P < 0.05) higher than the FSV group when the Bovela® BVDV type 1
virus was used as the recall antigen. When the Bovela® BVDV type 2
virus was used as the recall antigen, the values for the Bovela® group
were signiﬁcantly higher than the FSV group for the CD4T cell subset
only. The FSV group did not have detectable CD25 responses to the
Bovela® BVDV type 1 virus. It did have signiﬁcantly higher responses to
the Bovela® BVDV type 2 virus for the CD8 and γδ TCR T cells compared
to the PBS group.
The mean IFNγ EI data is shown in Fig. 6. There were no signiﬁcant
diﬀerences between groups before animal inoculation. The Bovela®
group had signiﬁcantly higher IFNγ ΕΙ for all T cell subsets when
stimulated with the Bovela® BVDV type 2 virus and for the CD4 and
CD8T cell subsets when stimulated with the Bovela® BVDV type 1 virus.
The FSV group had signiﬁcantly higher IFNγ EI for CD8T cell responses
to the Bovela® BVDV type 2 virus compared to the PBS group only.
The mean IL-4 EI data is shown in Fig. 7. There were no signiﬁcant
diﬀerences between groups before the experiment. The Bovela® group
had signiﬁcantly higher IL-4 EI responses in CD4 and CD8T cell subsets
when stimulated with Bovela® BVDV type 1 virus, and CD4T cell subset
responses when stimulated with Bovela® BVDV type 2 virus. The FSV
group did not have signiﬁcantly higher IL-4 EI responses to any recall
viruses for any T cell subsets.
4. Discussion
The Bovela® vaccine has signiﬁcant safety advantages compared to
other MLV BVD vaccines. It has previously been shown to be safe in
pregnant heifers and cows and to be incapable of crossing the placenta
(Meyer et al., 2007). In this manuscript we demonstrated an additional
safety advantage, that Bovela® vaccine did not induce lymphopenia.
Virulent BVDV and a MLV BVDV vaccine have previously been shown
to decrease both lymphocyte and neutrophil numbers in blood (Roth
et al., 1981; Roth and Kaeberle, 1983). Inoculation with FSV induced a
decrease in both neutrophils and lymphocytes. The Bovela® vaccine also
induced a numerical decrease in platelet numbers, but it was not
signiﬁcantly diﬀerent (P < 0.05) from the values for the PBS group.
The FSV induced a decrease in platelet count, which were signiﬁcantly
lower than the PBS group. This has previously been shown with BVDV
challenge (Marshall et al., 1996; Platt et al., 2009). The platelet counts
Fig. 5. Mean CD25 (± SEM) Expression Indices of each treatment group were analyzed and compared by T cell subset. Results from weeks 5, 6, and 7 were combined. Statistical analysis
was performed. Each error bar is constructed using 1 standard error from the mean. Levels, within the same subset, not connected by same letter are signiﬁcantly diﬀerent (p < 0.05).
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for the FSV group were signiﬁcantly lower than the values for the
Bovela® group both before and after virus inoculation. The lower counts
before vaccination/FSV inoculation were apparently due to random
chance, therefore the values after vaccination/FSV inoculation are
diﬃcult to interpret.
The Bovela® vaccine induced SVN antibody titers to both BVDV
types 1 and 2. The FSV inoculation induced SVN antibody titers to
BVDV type 1 similar to the titers induced by Bovela® vaccine. The
antibody titers to BVDV type 2 were much higher for the FSV group
than for the Bovela® group. This may be due to the much higher titer of
BVD type 2 FSV administered (2 × 107 TCID50) to the calves as
compared to the dose of virus in Bovela® vaccine (103 TCID50 of each
strain). The SVN titers were to heterologous viruses in all cases. The
relatedness of the Bovela® vaccine viruses and FSV to the heterologous
viruses used in the SVN assay may have inﬂuenced the observed titers.
The Bovela® vaccine has eﬃcacy advantages as compared to killed
vaccine. It induced memory CD4, CD8, and γδ TCR T cells to
homologous BVDV types 1 and 2 when evaluated using surface
expression of CD25 as the activation marker. Other MLV BVDV vaccines
have previously been shown to induce all three types of memory T cells
(Platt et al., 2006; Platt et al., 2009). A killed BVDV vaccine failed to
induce detectable CD8 T cell responses (Platt et. al., 2008), apparently
because the killed virus did not induce synthesis of BVD virus proteins
in the cytoplasm which is important for antigen presentation on MHC I
molecules for recognition by CD8T cells. The Bovela® vaccine also
induced signiﬁcant upregulation of intracellular expression of IFNγ in
both CD4 and CD8T cells in response to homologous BVDV types 1 and
2 recall viruses. The γδ TCR T cells only had signiﬁcant upregulation of
IFNγ when restimulated with homologous BVDV type 2. Induction of
memory CD4, CD8, and γδ TCR T cells by virulent virus (Endsley et al.,
2004) and by an MLV BVD vaccine (Platt et al., 2009), in the presence
of maternal antibody has previously been shown to induce all three
types of memory T cells without inducing measurable antibody
responses and to provide protection from challenge with virulent type
2 BVD virus (Ridpath et al., 2003).
5. Conclusions
The Bovela® live double deleted vaccine combines some of the safety
advantages of killed BVDV vaccines and some of the eﬃcacy advan-
tages of MLV BVD vaccines. In contrast to other MLV BVD vaccines, it
has previously been shown to be safe for use in seronegative pregnant
heifers and cows (Meyer et al., 2007) and we demonstrated here that it
does not induce a lymphopenia after vaccination. In contrast to a killed
Fig. 6. Mean (± SEM) IFNγ Expression Indices of each treatment group were analyzed and compared by T cell subset. Results from weeks 5, 6, and 7 were combined. Each error bar is
constructed using 1 standard error of the mean. Levels, within the same subset, not connected by same letter are signiﬁcantly diﬀerent (p < 0.05).
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BVDV vaccine, Bovela® is capable of inducing memory CD8 (cytotoxic)
T cells to the homologous BVDV types 1 and 2 viruses. The Bovela® live
double deleted vaccine provides a potentially important new tool for
control of BVD virus infections in pregnant animals and their fetuses.
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